Related Experiment Video
Updated: Aug 12, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
[Surgical treatment of multidrug resistant pulmonary tuberculosis cases]
1Department of Thoracic Surgery, Fukujuuji Hospital, JATA, Tokyo, Japan.
Unlabelled:
We report on the results of surgical treatment of pulmonary tuberculosis cases intractable to ordinary therapy due to acquired drug-resistance against multiple anti-tuberculosis drugs (MDR-Tbc).
Material And Method:
From 1983 to 1994, 54 patients were administered surgical treatments (60 interventions in all) for pulmonary tuberculosis. Among them, 46 were MDR Tbc cases (52 interventions in all) and were enrolled for this study. The Japanese criteria for drug resistance were referred to, the threshold of resistance in each drug being as follows, INH 0.1, RFP 50, EB 2.5, SM 20, KM 100, TH 25, EVM 100, CPM 100, CS 40, PAS 1 microgram/ml. Bacteriological examinations of sputa were repeated in the postoperative period until upto several years, and the continued absence of Tbc. bacilli for more than 12 months was considered as cured.
Results:
(1) 37 patients underwent removal of lung mass including tuberculous foci mainly fibrous cavitary lesions (40 interventions in all). The procedures are as follows 22 upper lobectomies and/or partial resections of adjacent lobes. 1 middle lobectomy. A lower lobectomy, 14 pneumonectomies, 2 segmentectomies. In 3 cases, multiple operations were carried out on 2 occasions; 2 upper lobectomies followed by completion pneumonectomies. 1 right upper lobectomy followed by left S3 segmentectomy. Except 2 cases having died of pneumonia and suicide within 12 months after operation, we have 38 cases available for evaluation. Bacteriological relapses were confirmed in 7 among 38 cases postoperatively. 2 of these 7 relapsed cases underwent additional completion pneumonectomies and attained complete cure. Bacteriological relapse-rate was therefore 18.4% (7/38) and the ultimate cure rate of pulmonary MDR-Tbc was 88.6% (31/35). (2) 7 patients underwent thoracoplasties (not corrective, once for each patient). In 2 cases bacteriological relapse was confirmed. Other 5 cases remained bacteriologically silent over a long postoperative period. (3) 4 patients underwent cavernostomies, 3 of them got satisfactory result in reducing the bacterial presence in the sputum (preoperative abundant bacilli (Gaffky 7, 8) turned mean-negative within 2 months after cavernostomy).
Conclusion:
With the above-mentioned results we conclude that surgical treatment is highly effective in intractable pulmonary MDR Tbc cases.
More Related Videos
03:47A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
Published on: October 25, 2024
10:24Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
Published on: May 22, 2026
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pneumothorax-II
Clinical Manifestations: